Abstract
Infliximab (IFX) is effective for treatment of refractory Kawasaki disease (KD). However, the precise mechanisms and biomarkers for IFX efficacy are unknown. We tried to evaluate the effect and response to IFX therapy by measuring serum cytokine levels. Twenty-nine children with KD who had been resistant to two courses of high-dose intravenous immunoglobulin were enrolled and treated with IFX. Plasma samples were analyzed for cytokines before and after IFX administration. Serum levels of interleukin-6, granulocyte colony-stimulating factor (G-CSF), interferon-gamma-induced monokine, interferon-gamma inducible protein 10 (IP-10), monocyte chemotactic protein 1, and soluble tumor necrosis factor-alpha receptor (sTNFR) 1 and 2 were significantly elevated before IFX treatment, but promptly decreased after the administration. The pre-treatment G-CSF and sTNFR1 levels in non-responders to IFX were significantly higher than in responders, who were defined as patients who defervesce (< 37.5 °C). After IFX administration, elevated cytokines declined to normal ranges in responders, but in non-responsive group, G-CSF and sTNFR1 remained elevated without failing to normal levels. IFX treatment significantly reduced the levels of serum cytokines, chemokines, and sTNFRs in refractory KD. G-CSF and sTNFR1 may be indicators predictive of poor response to IFX.
Similar content being viewed by others
References
Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 16(3):178–222
Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T (1984) High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2(8411):1055–1058
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, American Academy of Pediatrics (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110(17):2747–2771. https://doi.org/10.1161/01.CIR.0000145143.19711.78
Wallace CA, French JW, Kahn SJ, Sherry DD (2000) Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105(6):E78. https://doi.org/10.1542/peds.105.6.e78
Sonoda K, Mori M, Hokosaki T, Yokota S (2014) Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr 164(5):1128–1132. https://doi.org/10.1016/j.jpeds.2014.01.020
Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T et al (2012) Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 39(4):864–867. https://doi.org/10.3899/jrheum.110877
Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW (2011) Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 158(4):644–649. https://doi.org/10.1016/j.jpeds.2010.10.012
Song MS, Lee SB, Sohn S, JH O, Yoon KL, Han JW, Kim CH (2010) Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J 40(7):334–338. https://doi.org/10.4070/kcj.2010.40.7.334
Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS et al (2008) Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2153:833–838
Burns JC, Shimizu C, Gonzalez E, Kulkarni H, Patel S, Shike H, Sundel RS, Newburger JW, Ahuja SK (2005) Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis 192(2):344–349. https://doi.org/10.1086/430953
Chen SY, Wan L, Huang YC, Sheu JJ, Lan YC, Lai CH et al (2009) Interleukin-18 gene 105A/C genetic polymorphism is associated with the susceptibility of Kawasaki disease. J Clin Lab Anal 23(2):71–76. https://doi.org/10.1002/jcla.20292
Kim DS (1992) Serum interleukin-6 in Kawasaki disease. Yonsei Med J 33(2):183–188. https://doi.org/10.3349/ymj.1992.33.2.183
Matsubara T, Furukawa S, Yabuta K (1990) Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 56(1):29–36. https://doi.org/10.1016/0090-1229(90)90166-N
Asano T, Ogawa S (2000) Expression of monocyte chemoattractant protein-1 in Kawasaki disease: the anti-inflammatory effect of gamma globulin therapy. Scand J Immunol 51(1):98–103. https://doi.org/10.1046/j.1365-3083.2000.00650.x
Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K (1994) Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 124(5):721–725. https://doi.org/10.1016/S0022-3476(05)81361-7
Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M (2008) Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol 122(5):1008–1013. https://doi.org/10.1016/j.jaci.2008.09.011
Ko TM, Kuo HC, Chang JS, Chen SP, Liu YM, Chen HW, Tsai FJ, Lee YC, Chen CH, Wu JY, Chen YT (2015) CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease. Circ Res 116(5):876–883. https://doi.org/10.1161/CIRCRESAHA.116.305834
Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD (1999) The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 162(6):3549–3558
Cassatella MA, Gasperini S, Calzetti F, Bertagnin A, Luster AD, McDonald PP (1997) Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol 27(1):111–115. https://doi.org/10.1002/eji.1830270117
Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184(3):963–969. https://doi.org/10.1084/jem.184.3.963
Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, Aikawa E, Moore KJ, Luster AD, Gerszten RE (2006) Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 113(19):2301–2312. https://doi.org/10.1161/CIRCULATIONAHA.105.605121
Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, Ishii M, Harada K, Kawasaki Disease Research Committee (2005) Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 47(2):232–234. https://doi.org/10.1111/j.1442-200x.2005.02033.x
Feng S, Yadav SK, Gao F, Yi Q (2015) Plasma levels of monokine induced by interferon-gamma/chemokine (C-X-X motif) ligand 9, thymus and activation-regulated chemokine/chemokine (C-C motif) ligand 17 in children with Kawasaki disease. BMC Pediatr 15(1):109. https://doi.org/10.1186/s12887-015-0424-6
Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y (2013) Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum 65(3):805–814. https://doi.org/10.1002/art.37815
Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, Watanabe K, Watanabe S, Uese K, Kanegane H, Origasa H, Ichida F, Roth J, Miyawaki T, Saji T (2009) Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 65(6):696–701. https://doi.org/10.1203/PDR.0b013e31819ed68d
Shigemura T, Yamazaki T, Hara Y, JN O, Stevens AM, Ochs HD et al (2011) Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Pediatr Rheumatol Online J 9(1):15. https://doi.org/10.1186/1546-0096-9-15
Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76(6):959–962. https://doi.org/10.1016/0092-8674(94)90372-7
Lantz M, Malik S, Slevin ML, Olsson I (1990) Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2(6):402–406. https://doi.org/10.1016/1043-4666(90)90048-X
Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113(22):2606–2612. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T (2006) Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149(2):237–240. https://doi.org/10.1016/j.jpeds.2006.03.050
Tang Y, Yan W, Sun L, Huang J, Qian W, Ding Y, Lv H (2016) Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population. Clin Rheumatol 35(11):2771–2776. https://doi.org/10.1007/s10067-016-3370-2
Gallo A, Saad A, Ali R, Dardik A, Tellides G, Geirsson A (2012) Circulating interferon-gamma-inducible Cys-X-Cys chemokine receptor 3 ligands are elevated in humans with aortic aneurysms and Cys-X-Cys chemokine receptor 3 is necessary for aneurysm formation in mice. J Thorac Cardiovasc Surg 143(3):704–710. https://doi.org/10.1016/j.jtcvs.2011.08.036
Acknowledgements
We thank Drs. Fumio Morohashi, Kuniaki Naganuma, Kesashi Aonuma, Akihiko Yabuhara, Takahisa Tsuno, Tetsuo Kubo, Yasushi Iwasaki, Ei Shimazaki, Takashi Shimizu, and Kenichi Koike for their invaluable contributions to the collection of patient samples.
Source of funding
This work was supported by a Health Labour Sciences Research Grant entitled Translational research toward the clarification of autoinflammatory mechanisms by familial Mediterranean fever (FMF) inflammasomes based on the Mediterranean fever (MEFV) gene analysis (15ek0109033h0002).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This investigation on IFX therapy for refractory KD and its analysis of cytokine profiles for KD were approved by the institutional review board of Shinshu University (No. 993 and 2781).
Informed consent
Informed consent was obtained from all individual participants included in the study.
Disclosures
None.
Rights and permissions
About this article
Cite this article
Hachiya, A., Kobayashi, N., Matsuzaki, S. et al. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients. Clin Rheumatol 37, 1937–1943 (2018). https://doi.org/10.1007/s10067-017-3952-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-017-3952-7